Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ANGN Angion Biomedica (ANGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Angion Biomedica Stock (NASDAQ:ANGN) 30 days 90 days 365 days Advanced Chart Remove Ads Get Angion Biomedica alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.00▼$10.0052-Week Range N/AVolume224,800 shsAverage Volume86,718 shsMarket Capitalization$30.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAngion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.Read More… Remove Ads Receive ANGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address ANGN Stock News HeadlinesAkari Therapeutics PLC ADRSeptember 19, 2024 | wsj.comOXBDF Oxford Biomedica plcJuly 31, 2024 | seekingalpha.comThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.March 31, 2025 | Golden Portfolio (Ad)Angion Biomedia Corp. Announces 1-for-10 Reverse Stock SplitJune 1, 2023 | finance.yahoo.com8-K: Angion Biomedica Corp.May 2, 2023 | marketwatch.comCompanies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite RiskyApril 27, 2023 | finance.yahoo.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CSII, ANGN, OSH, NUVAApril 11, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, ANGN, TIGApril 6, 2023 | markets.businessinsider.comSee More Headlines ANGN Stock Analysis - Frequently Asked Questions How were Angion Biomedica's earnings last quarter? Angion Biomedica Corp. (NASDAQ:ANGN) issued its earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.30) by $2.00. The firm earned $1.46 million during the quarter, compared to analysts' expectations of $1.08 million. When did Angion Biomedica's stock split? Angion Biomedica's stock reverse split before market open on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Angion Biomedica IPO? Angion Biomedica (ANGN) raised $75 million in an IPO on Friday, February 5th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Stifel served as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers. What other stocks do shareholders of Angion Biomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Angion Biomedica investors own include Evofem Biosciences (EVFM), Plug Power (PLUG), CNS Pharmaceuticals (CNSP), Viking Therapeutics (VKTX), ContextLogic (WISH), Abeona Therapeutics (ABEO) and Applied Genetic Technologies (AGTC). Company Calendar Last Earnings11/12/2021Today3/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ANGN CIK1601485 Webwww.angion.com Phone415-655-4899FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,810,000.00 Net MarginsN/A Pretax Margin-4,456.97% Return on Equity-47.53% Return on Assets-40.55% Debt Debt-to-Equity RatioN/A Current Ratio20.00 Quick Ratio20.00 Sales & Book Value Annual Sales$2.30 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / BookN/AMiscellaneous Outstanding Shares30,110,000Free Float24,182,000Market Cap$30.11 million OptionableNot Optionable Beta0.60 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:ANGN) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Angion Biomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Angion Biomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.